CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent).

克利夫兰和肯塔基州列克星敦-（商业线）-Athersys，Inc。（纳斯达克股票代码：ATHX），一家开发用于重症监护适应症的MultiStem®（invimestrocel）的细胞疗法和再生医学公司，以及多能成体祖细胞（MAPC®）马，犬和猫健康应用技术，宣布与Ardent Animal health（Ardent）签署许可协议。

Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies for animals..

Ardent是一家私营兽医生物技术公司，为动物开发再生医学和癌症疗法。。

Under the terms of the agreement, Athersys will receive an initial fee from Ardent in exchange for an exclusive license to Athersys’ Multipotent Adult Progenitor Cell (MAPC®) technology for non-human mammal applications in the United States. The agreement includes pre- and post-regulatory approval milestone payments to Athersys, including payments on conditional and full product approval for each species/indication combination.

根据协议条款，Athersys将从Ardent收取初始费用，以换取Athersys在美国用于非人类哺乳动物应用的多能成体祖细胞（MAPC®）技术的独家许可。该协议包括对Athersys的监管前和监管后批准里程碑付款，包括每种物种/适应症组合的有条件和完整产品批准付款。

Athersys will also receive tiered, double-digit royalties on commercial sales..

Athersys还将在商业销售中获得分层，两位数的版税。。

Athersys has also granted Ardent rights of first refusal to be the exclusive distributor for Athersys’ novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU) in the United States animal health space.

Athersys还授予了优先拒绝作为Athersys新型低温存储系统，美国动物健康空间安全集成冷冻单元（SIFU）独家经销商的权利。

“We’re excited to announce this agreement with Ardent based on their proven capabilities in developing stem cell-based treatment options for animals. This agreement recognizes the progress we’ve made in preclinical research and manufacturing of MAPC for animal health and provides Ardent a solid foundation to build on,” stated Dan Camardo, Chief Executive Officer of Athersys..

“我们很高兴能够基于他们在开发基于干细胞的动物治疗方案方面的能力，以热情地宣布这项协议。该协议认识到我们在动物健康MAPC临床前研究和制造方面取得的进展，并为热情提供了坚实的基础建立起来，”Athersys首席执行官Dan Camardo说。。

“We look forward to this partnership with Athersys as we develop innovative and life-changing treatments for animals. Through partnerships like this and with the strong results generated to date with MAPC, we’re better able to advance stem cell therapy for joint disease and other areas of unmet need in animal health,” added Thomas Masterson, President of Ardent..

“我们期待与Athersys建立这种伙伴关系，因为我们为动物开发创新和改变生活的治疗方法。通过这样的伙伴关系以及迄今为止MAPC产生的强大成果，我们能够更好地推进干细胞治疗关节疾病和其他动物健康需求未得到满足的领域，”Ardent总裁Thomas Masterson补充道。。

About Ardent Animal Health

关于热情的动物健康

Ardent Animal Health is a veterinary biotechnology company based in Lexington, Kentucky. Founded in 2016, its mission is to improve the lives of pets and people. Ardent’s pipeline includes novel cancer and regenerative medicine treatments for veterinary patients suffering from cancer and other inflammatory diseases.

Ardent Animal Health是位于肯塔基州列克星敦的兽医生物技术公司。成立于2016年，其使命是改善宠物和人的生活。Ardent的管道包括针对患有癌症和其他炎症性疾病的兽医患者的新型癌症和再生医学治疗。

Ardent is a synonym for passionate, fiery and committed, which manifests through Ardent’s worldwide referral network providing advanced care for complicated diseases. Ardent is a Breakthru Portfolio company (see www.realbreakthru.com). For more information, please visit https://ardentanimalhealth.com/..

Ardent是热情，热情和忠诚的代名词，通过Ardent的全球转诊网络为复杂疾病提供高级护理。Ardent是Breakthru投资组合公司（请参阅www.realbreakthru.com）。有关更多信息，请访问https://ardentanimalhealth.com/..

About MultiStem®

关于MultiStem®

MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage.

MultiStem®（invimestrocel）细胞疗法是临床开发中获得专利的再生医学产品，具有以各种方式促进组织修复和愈合的能力，例如通过响应炎症和组织信号产生治疗因子损伤。

MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique 'off-the-shelf' stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression.

多干细胞疗法对多维治疗效果的潜力将其与专注于单一益处机制的传统生物制药疗法区分开来。该疗法代表了一种独特的“现成”干细胞产品，可以以可扩展的方式制造，可以以冷冻形式储存多年，并且在没有组织匹配或需要免疫抑制的情况下施用。

Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need..

基于其疗效特征，其新的作用机制以及临床研究中证明的有利和一致的耐受性，我们认为多干细胞治疗可以为患者提供有意义的益处，包括患有严重疾病和未满足医疗需求的患者。。

About Athersys

关于阿瑟斯

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product.

Athersys是一家生物技术公司，致力于发现和开发旨在延长和提高人类生活质量的候选治疗产品。Athersys正在开发其MultiStem®细胞治疗产品，这是一种专利的成人衍生“现成”干细胞产品，最初用于神经系统，炎症和免疫以及其他重症监护适应症的疾病适应症，并且有几个正在进行的临床试验评估这种潜在的再生医学产品。

Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. While development of our clinical programs for human health indications remains our priority, our wholly owned subsidiary, ReGenesys developed a cell therapy based on Athersys’ Multipotent Adult Progenitor Cell (MAPC®) technology for use in treating diseases and conditions in the animal health area.

Athersys已经建立了战略合作伙伴关系和广泛的合作网络，以进一步推动多干细胞疗法向商业化方向发展。虽然我们的人类健康适应症临床计划的开发仍然是我们的优先事项，但我们的合资子公司ReGenesys开发了一种基于Athersys多能成体祖细胞（MAPC®）技术的细胞疗法，用于治疗动物健康领域的疾病和病症。

We have conducted research in preclinical canine, equine and feline models to establish safety and explore the potential for MAPC cells to reduce inflammation and promote healing which could provide meaningful benefits to animals. Investors and others should note that we may post information about Athersys on its website at www.athersys.com and/or on its accounts on Twitter, Facebook, LinkedIn or other social media platforms.

我们已经在临床前犬，马和猫模型中进行了研究，以建立安全性并探索MAPC细胞减少炎症和促进愈合的潜力，这可以为动物提供有意义的益处。投资者和其他人应注意，我们可能会在其网站www.Athersys.com和/或其在Twitter，Facebook，LinkedIn或其他社交媒体平台上的帐户上发布有关Athersys的信息。

It is possible that the postings could include information deemed to be material information. Therefore, Athersys encourages investors, the media and others interested in Athersys to review the information it posts on its website at www.athersys.com and on its social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys.

帖子可能包含被视为材料信息的信息。因此，Athersys鼓励投资者，媒体和对Athersys感兴趣的其他人审查其在www.Athersys.com网站上发布的信息及其社交媒体帐户。请访问Twitter上的Athersys，网址为www.Twitter.com/Athersys。

Information that Athersys may post about itself on its website and/or on its .

Athersys可能会在其网站和/或其网站上发布有关其自身的信息。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of product candidates, Athersys’ growth strategy, and its future financial performance, including its operations, economic performance, financial condition, prospects, and other future events, and any results from the license to Ardent and any revenues to Athersys as a result of such license.

本新闻稿包含1995年“私人证券诉讼改革法”含义内涉及风险和不确定性的前瞻性陈述。这些前瞻性陈述除其他外，还涉及产品候选人开发的预期时间表，Athersys的成长战略及其未来的财务绩效，包括其运营，经济绩效，财务状况，前景和其他未来事件，以及由于这种许可证，从Ardent许可证和Athersys的任何收入的任何结果。

Athersys has attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on Athersys’ current expectations.

Athersys试图通过使用“预期”，“相信”，“可以”，“继续”，“可以”，“估计”，“期望”，“意图”，“可能”，“计划”，“潜力”，“应该”，“建议”，“意愿”或其他类似的表达方式来识别前瞻性陈述。这些前瞻性陈述只是预测，主要基于Athersys目前的预期。

In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that Athersys faces are the risk that it will be unable to raise capital to fund its operations in the near term and long term, including its ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to it or at all, and to continue as a going concern.

此外，一些已知和未知的风险，不确定性和其他因素可能会影响这些陈述的准确性。Athersys面临的一些更重要的已知风险是其无法筹集资金以在近期和长期为其运营提供资金的风险，包括其通过公共或私募股权发行获得资金的能力，债务融资，合作和许可安排或其他来源，按其可接受或根本无法接受的条款，并继续关注。

The following risks and uncertainties may cause Athersys’ actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: its ability to raise capital to fund its operations .

以下风险和不确定性可能导致Athersys的实际结果，活动水平，绩效或成就与这些前瞻性陈述所表达或暗示的任何未来结果，活动水平，绩效或成就大不相同：其筹集资金为其运营提供资金。